Immuron is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a class of polyclonal antibodies. Co.'s oral polyclonal antibodies provide delivery within the gastrointestinal track but do not cross into the bloodstream. Co. markets its commercial products Travelan® and Protectyn® in Australia, both products are listed medicines on the Australian Register for Therapeutic Goods. Co. also markets Travelan® in Canada where it is licensed as a natural health product indicated to reduce the risk of travelers' diarrhea, and market Travelan® as a dietary supplement for digestive tract protection. The IMRN average annual return since 2017 is shown above.
The Average Annual Return on the IMRN average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether IMRN average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the IMRN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free IMRN Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
